Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W M Smit

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
The Netherlands Journal of Medicine|September 30, 2010
Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancerJ R Kroep, S C Linn, E Boven, et al.
British Journal of Cancer|November 8, 2006
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapyJ Hannemann, P Kristel, H van Tinteren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2012
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel studyA K L Reyners, L de Munck, F L G Erdkamp, et al.
Bone Marrow Transplantation|July 16, 2008
Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patientsP Nieboer, E G E de Vries, N H Mulder, et al.
Annals of Hematology|October 13, 2006
High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III studyW Deenik, B van der Holt, G E G Verhoef, et al.
European Journal of Haematology|February 17, 2025
Treatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML PatientsC Kockerols, P J M Valk, P Hogenbirk, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
The Netherlands Journal of Medicine|September 30, 2010
Lapatinib: clinical benefit in patients with HER 2-positive advanced breast cancerJ R Kroep, S C Linn, E Boven, et al.
British Journal of Cancer|November 8, 2006
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapyJ Hannemann, P Kristel, H van Tinteren, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 13, 2012
A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel studyA K L Reyners, L de Munck, F L G Erdkamp, et al.
Bone Marrow Transplantation|July 16, 2008
Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patientsP Nieboer, E G E de Vries, N H Mulder, et al.
Annals of Hematology|October 13, 2006
High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III studyW Deenik, B van der Holt, G E G Verhoef, et al.
European Journal of Haematology|February 17, 2025
Treatment-Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML PatientsC Kockerols, P J M Valk, P Hogenbirk, et al.
Pageof 3